SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 24, 2003
Savient Pharmaceuticals, Inc.
(Exact name of issuer as specified in its charter)
Delaware | | 0-15313 | | 13-3033811 |
(State or Other Jurisdiction | | (Commission File Number) | | (IRS Employer |
of Incorporation) | | | | Identification No.) |
| | | | |
One Tower Center, 14th Floor | | | | |
East Brunswick, New Jersey | | | | 08816 |
(Address of Principal Executive Offices) | | | | (Zip Code) |
| | | | |
| | | | |
Registrant’s telephone number, including area code: (732) 418-9300 |
| | | | |
None. |
(Former Name or Former Address, if Changed Since Last Report.) |
| | | | | | | | |
ITEM 5. OTHER EVENTS AND REQUIRED FD DISCLOSURE.
On December 24, 2003, Savient Pharmaceuticals, Inc. issued the press release filed herewith as Exhibit 99.1
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
(c) Exhibits.
99.1 Press release issued by Saveint Pharmaceuticals, Inc. on December 24, 2003.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| SAVIENT PHARMACEUTICALS, INC. |
| (Registrant) |
| |
| |
| By: | /s/ Sim Fass |
| | Sim Fass |
| | Chairman and Chief Executive Officer |
| | |
| | |
Dated: December 24, 2003 | | |
3
